Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 1
1985 6
1986 9
1987 4
1988 2
1989 5
1990 4
1991 4
1992 4
1993 4
1994 3
1995 4
1996 1
1997 5
1998 2
1999 1
2000 3
2001 3
2002 3
2003 2
2004 3
2006 3
2007 7
2008 9
2010 1
2011 2
2012 8
2013 5
2014 4
2015 6
2016 6
2017 4
2018 12
2019 12
2020 10
2021 15
2022 14
2023 16
2024 21
2025 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

226 results

Results by year

Filters applied: . Clear all
Page 1
Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.
Northrup H, Aronow ME, Bebin EM, Bissler J, Darling TN, de Vries PJ, Frost MD, Fuchs Z, Gosnell ES, Gupta N, Jansen AC, Jóźwiak S, Kingswood JC, Knilans TK, McCormack FX, Pounders A, Roberds SL, Rodriguez-Buritica DF, Roth J, Sampson JR, Sparagana S, Thiele EA, Weiner HL, Wheless JW, Towbin AJ, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Northrup H, et al. Pediatr Neurol. 2021 Oct;123:50-66. doi: 10.1016/j.pediatrneurol.2021.07.011. Epub 2021 Jul 24. Pediatr Neurol. 2021. PMID: 34399110 Free article.
Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial.
Hordinsky M, Hebert AA, Gooderham M, Kwon O, Murashkin N, Fang H, Harada K, Law E, Wajsbrot D, Takiya L, Zwillich SH, Wolk R, Tran H. Hordinsky M, et al. Among authors: hebert aa. Pediatr Dermatol. 2023 Nov-Dec;40(6):1003-1009. doi: 10.1111/pde.15378. Epub 2023 Jul 17. Pediatr Dermatol. 2023. PMID: 37455588 Clinical Trial.
Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials.
Silverberg JI, Eichenfield LF, Hebert AA, Simpson EL, Stein Gold L, Bissonnette R, Papp KA, Browning J, Kwong P, Korman NJ, Brown PM, Rubenstein DS, Piscitelli SC, Somerville MC, Tallman AM, Kircik L. Silverberg JI, et al. Among authors: hebert aa. J Am Acad Dermatol. 2024 Sep;91(3):457-465. doi: 10.1016/j.jaad.2024.05.023. Epub 2024 May 20. J Am Acad Dermatol. 2024. PMID: 38777187 Free article. Clinical Trial.
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.
Simpson EL, Eichenfield LF, Alonso-Llamazares J, Draelos ZD, Ferris LK, Forman SB, Gooderham M, Gonzalez ME, Hebert AA, Kircik LH, Lomaga M, Moore A, Papp KA, Prajapati VH, Hanna D, Snyder S, Krupa D, Burnett P, Almaraz E, Higham RC, Chu DH, Berk DR. Simpson EL, et al. Among authors: hebert aa. JAMA Dermatol. 2024 Nov 1;160(11):1161-1170. doi: 10.1001/jamadermatol.2024.3121. JAMA Dermatol. 2024. PMID: 39292443 Free PMC article. Clinical Trial.
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.
Blauvelt A, Draelos ZD, Stein Gold L, Alonso-Llamazares J, Bhatia N, DuBois J, Forman SB, Gooderham M, Green L, Guenthner ST, Hebert AA, Lain E, Moore AY, Papp KA, Zirwas M, Kato S, Snyder S, Krupa D, Burnett P, Berk DR, Chu DH. Blauvelt A, et al. Among authors: hebert aa. J Am Acad Dermatol. 2024 May;90(5):986-993. doi: 10.1016/j.jaad.2023.12.065. Epub 2024 Jan 20. J Am Acad Dermatol. 2024. PMID: 38253129 Free article. Clinical Trial.
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, Eichenfield LF, Forsha DW, Rees WC, Simpson EL, Spellman MC, Stein Gold LF, Zaenglein AL, Hughes MH, Zane LT, Hebert AA. Paller AS, et al. Among authors: hebert aa. J Am Acad Dermatol. 2016 Sep;75(3):494-503.e6. doi: 10.1016/j.jaad.2016.05.046. Epub 2016 Jul 11. J Am Acad Dermatol. 2016. PMID: 27417017 Free article. Clinical Trial.
Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials.
Hebert AA, Flohr C, Hong HC, Irvine AD, Pierce E, Elmaraghy H, Pillai S, Dawson Z, Chen S, Armengol C, Siegfried E, Weidinger S. Hebert AA, et al. J Dermatolog Treat. 2024 Dec;35(1):2324833. doi: 10.1080/09546634.2024.2324833. Epub 2024 May 12. J Dermatolog Treat. 2024. PMID: 38735650 Free article. Clinical Trial.
Peutz-Jeghers syndrome.
Kitagawa S, Townsend BL, Hebert AA. Kitagawa S, et al. Among authors: hebert aa. Dermatol Clin. 1995 Jan;13(1):127-33. Dermatol Clin. 1995. PMID: 7712638 Review.
226 results